Top Markets
Coin of the day
Lumosa Therapeutics Co., Ltd. Lumosa Therapeutics Co., Ltd.

Lumosa Therapeutics Co., Ltd.

6535
Clasificación en acciones #14759
Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company,... Lumosa Therapeutics Co., Ltd. is a clinical-stage pharmaceutical company, headquartered in Taiwan, focused on developing innovative therapies for neurological and oncological diseases. Its most advanced product, LT-1001, an injectable analgesic, has completed Phase III clinical trials for the management of severe post-operative pain. The company's pipeline also includes LT3001, currently in Phase II for treating acute ischemic stroke; LT5001, which has finished Phase Ib trials for uremic pruritus; and LT2003, an oncology drug candidate in its preclinical development stage. Founded in 2000, Lumosa Therapeutics maintains its operational base in Taipei.
Precio por acción
$2.35
Capitalización bursátil
$394.12M
Cambio (1 día)
-1.07%
Cambio (1 año)
-64.75%
País
TW
Comercio Lumosa Therapeutics Co., Ltd. (6535)

Categoría

Ratio P/B de Lumosa Therapeutics Co., Ltd. (6535)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Lumosa Therapeutics Co., Ltd., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Lumosa Therapeutics Co., Ltd. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras
Empresa Ratio P/B Diferencia del ratio P/B País
6.828 -
US
7.5116 -
NL
3.9942 -
AU
8.2199 -
US
- -
CH